{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:25:37Z","timestamp":1782707137231,"version":"3.54.5"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>We aimed to investigate how changes in direct bilirubin (DBiL) levels in severely\/critically ill the coronavirus disease (COVID-19) patients during their first week of hospital admission affect their subsequent prognoses and mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively enrolled 337 severely\/critically ill COVID-19 patients with two consecutive blood tests at hospital admission and about 7 days after. Based on the trend of the two consecutive tests, we categorized patients into the normal direct bilirubin (DBiL) group (224), declined DBiL group (44) and elevated DBiL group (79).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The elevated DBiL group had a significantly larger proportion of critically ill patients (\u03c7<jats:sup>2<\/jats:sup>-test, <jats:italic>p<\/jats:italic> &amp;lt; 0.001), a higher risk of ICU admission, respiratory failure, and shock at hospital admission (\u03c7<jats:sup>2<\/jats:sup>-test, all <jats:italic>p<\/jats:italic> &amp;lt; 0.001). During hospitalization, the elevated DBiL group had significantly higher risks of shock, acute respiratory distress syndrome (ARDS), and respiratory failure (\u03c7<jats:sup>2<\/jats:sup>-test, all <jats:italic>p<\/jats:italic> &amp;lt; 0.001). The same findings were observed for heart damage (\u03c7<jats:sup>2<\/jats:sup>-test, <jats:italic>p<\/jats:italic> = 0.002) and acute renal injury (\u03c7<jats:sup>2<\/jats:sup>-test, <jats:italic>p<\/jats:italic> = 0.009). Cox regression analysis showed the risk of mortality in the elevated DBiL group was 2.27 (95% CI: 1.50\u20133.43, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) times higher than that in the normal DBiL group after adjusted age, initial symptom, and laboratory markers. The Receiver Operating Characteristic curve (ROC) analysis demonstrated that the second test of DBiL was consistently a better indicator of the occurrence of complications (except shock) and mortality than the first test in severely\/critically ill COVID-19 patients. The area under the ROC curve (AUC) combined with two consecutive DBiL levels for respiratory failure and death was the largest.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Elevated DBiL levels are an independent indicator for complication and mortality in COVID-19 patients. Compared with the DBiL levels at admission, DBiL levels on days 7 days of hospitalization are more advantageous in predicting the prognoses of COVID-19 in severely\/critically ill patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.843505","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T01:52:56Z","timestamp":1648605176000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Effect of Direct Bilirubin Level on Clinical Outcome and Prognoses in Severely\/Critically Ill Patients With COVID-19"],"prefix":"10.3389","volume":"9","author":[{"given":"Wensen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaolin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoru","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihua","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"B1","year":"2020","journal-title":"Timeline: WHO\u2019s COVID-19 Response."},{"key":"B2","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review.","volume":"324","author":"Wiersinga","year":"2020","journal-title":"Jama."},{"key":"B3","year":"2022","journal-title":"WHO Coronavirus (COVID-19) Dashboard."},{"key":"B4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.5603\/ARM.a2021.0041","article-title":"Coronavirus disease 2019 (COVID-19): a brief overview of features and current treatment.","volume":"89","author":"Al-Iede","year":"2021","journal-title":"Adv Respir Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/liv.14730","article-title":"Pathophysiological mechanisms of liver injury in COVID-19.","volume":"41","author":"Nardo","year":"2021","journal-title":"Liver Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1056\/NEJMc2011400","article-title":"Multiorgan and renal tropism of SARS-CoV-2.","volume":"383","author":"Puelles","year":"2020","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/hep.31487","article-title":"Abnormal liver tests in COVID-19: a retrospective observational cohort study of 1,827 patients in a major U.S. hospital network.","volume":"72","author":"Hundt","year":"2020","journal-title":"Hepatology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2147\/cia.S303629","article-title":"Dynamic changes in liver function tests and their correlation with illness severity and mortality in patients with COVID-19: a retrospective cohort study.","volume":"16","author":"Xu","year":"2021","journal-title":"Clin Interv Aging."},{"key":"B9","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1111\/liv.14435","article-title":"Liver injury during highly pathogenic human coronavirus infections.","volume":"40","author":"Xu","year":"2020","journal-title":"Liver Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/liv.14854","article-title":"COVID-19 and the liver \u2013 lessons learned.","volume":"41","author":"Herta","year":"2021","journal-title":"Liver Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/gutjnl-2020-322072","article-title":"Involvement of liver in COVID-19: systematic review and meta-analysis.","volume":"70","author":"Yadav","year":"2021","journal-title":"Gut."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1111\/liv.14477","article-title":"Bilirubin levels in patients with mild and severe covid-19: a pooled analysis.","volume":"40","author":"Paliogiannis","year":"2020","journal-title":"Liver Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.3748\/wjg.v27.i22.3022","article-title":"Liver injury in COVID-19: detection, pathogenesis, and treatment.","volume":"27","author":"Cai","year":"2021","journal-title":"World J Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.14218\/jcth.2020.00171","article-title":"Coronavirus disease 2019 and liver injury: a retrospective analysis of hospitalized patients in New York City.","volume":"9","author":"Bender","year":"2021","journal-title":"J Clin Transl Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jhep.2020.12.012","article-title":"Association of liver abnormalities with in-hospital mortality in patients with COVID-19.","volume":"74","author":"Ding","year":"2021","journal-title":"J Hepatol."},{"key":"B16","first-page":"5134","article-title":"Direct bilirubin as a prognostic biomarker in enteric fistula patients complicated with sepsis: a case-control study.","volume":"7","author":"Wu","year":"2014","journal-title":"Int J Clin Exp Med."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2021-000625","article-title":"Prognostic value of bilirubin and drug interactions.","volume":"8","author":"Ng","year":"2021","journal-title":"BMJ Open Gastroenterol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.598870","article-title":"Bilirubin levels as potential indicators of disease severity in coronavirus disease patients: a retrospective cohort study.","volume":"7","author":"Liu","year":"2020","journal-title":"Front Med (Lausanne)."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14557","article-title":"A new parameter for predict the clinical outcome of patients with COVID-19 pneumonia: the direct\/total bilirubin ratio.","volume":"75","author":"Ara\u00e7","year":"2021","journal-title":"Int J Clin Pract."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3760\/j.issn.1673-4777.2020.10.002","article-title":"New coronavirus pneumonia diagnosis and treatment plan (Trial Eighth Edition).","volume":"15","author":"Xiaolin","year":"2020","journal-title":"Chin Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1001\/jama.2012.5669","article-title":"Acute respiratory distress syndrome: the Berlin definition.","volume":"307","author":"Ranieri","year":"2012","journal-title":"Jama."},{"key":"B22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/B978-032304841-5.50044-3","article-title":"Nonpulmonary causes of respiratory failure.","author":"Lotano","year":"2008","journal-title":"Critical Care Medicine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the heart failure association (HFA) of the ESC.","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.ajkd.2013.02.349","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury.","volume":"61","author":"Palevsky","year":"2013","journal-title":"Am J Kidney Dis."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248675","article-title":"The effect of age on the clinical and immune characteristics of critically ill patients with COVID-19: a preliminary report.","volume":"16","author":"Hu","year":"2021","journal-title":"PLoS One."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.647303","article-title":"Liver and kidney function biomarkers, blood cell traits and risk of severe COVID-19: a mendelian randomization study.","volume":"12","author":"Wang","year":"2021","journal-title":"Front Genet."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14705","article-title":"Severe COVID-19 associated with liver injury in patients without preexisting liver disease.","volume":"13","author":"Altaf","year":"2021","journal-title":"Cureus."},{"key":"B28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.siny.2009.10.005","article-title":"Controversies in bilirubin biochemistry and their clinical relevance.","volume":"15","author":"McDonagh","year":"2010","journal-title":"Semin Fetal Neonatal Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.siny.2004.11.001","article-title":"Ontogeny of drug metabolizing enzymes in the neonate.","volume":"10","author":"Blake","year":"2005","journal-title":"Semin Fetal Neonatal Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00424-006-0109-y","article-title":"The apical conjugate efflux pump ABCC2 (MRP2).","volume":"453","author":"Nies","year":"2007","journal-title":"Pflugers Arch."},{"key":"B31","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s13238-020-00718-6","article-title":"Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids.","volume":"11","author":"Zhao","year":"2020","journal-title":"Protein Cell."},{"key":"B32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.stem.2020.06.015","article-title":"A human pluripotent stem cell\u2013based platform to study sars-cov-2 tropism and model virus infection in human cells and organoids.","volume":"27","author":"Yang","year":"2020","journal-title":"Cell Stem Cell."},{"key":"B33","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/MCC.0b013e32835ec9e6","article-title":"Hypoxic liver injury and cholestasis in critically ill patients.","volume":"19","author":"Horvatits","year":"2013","journal-title":"Curr Opin Crit Care."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/jamainternmed.2020.2033","article-title":"Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19.","volume":"180","author":"Liang","year":"2020","journal-title":"JAMA Intern Med."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03123-x","article-title":"Development and validation of a risk factor-based system to predict short-term survival in adult hospitalized patients with COVID-19: a multicenter, retrospective, cohort study.","volume":"24","author":"Zhang","year":"2020","journal-title":"Crit Care."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.843505\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T01:52:59Z","timestamp":1648605179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.843505\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":35,"alternative-id":["10.3389\/fmed.2022.843505"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.843505","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"article-number":"843505"}}